Myriad Genetics Signs Marketing Plans With Pfizer For BRACAnalysis CDx Test
Myriad Genetics, Inc. and Pfizer Inc. signed an agreement to promote Myriad's BRACAnalysis CDx test, currently under US FDA review, as a companion diagnostic for Pfizer's investigational breast cancer drug, talazoparib.
You may also be interested in...
Pacts In Medtech: Myriad/Pfizer Deal Headlines Oncology-Heavy List Of Deals In September And October
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in September and October 2018.
Liquid biopsies – carrying out diagnostic tests on liquid samples such as blood or urine rather than on tissue biopsy material – look set to revolutionize the management of cancer patients. This area has recently captured the interest of a growing number of diagnostic players, both big and small, and spawned the development of different approaches to liquid biopsy. This article marks out who's who in this increasingly busy landscape and the key technologies that are showing promise, and looks at the obstacles that companies are facing.
Japan-based Canon plans to launch a US-based medical imaging company near Cleveland to strengthen its US presence and competitiveness in the marketplace.